Tanabe Pharma Corporation
田邊製藥
- Headquarters
- Osaka, Japan
Clinical-stage assets
| Asset | Stage at source date | Indication | Source date |
|---|---|---|---|
| MT-2990 | Clinical stage; evaluated in clinical studies | Not disclosed | 2026-09-28 |
Licensing announcements since 2025
| Date | Counterparty | Asset / platform | Upfront | Near-term | Potential total | Stage at announcement |
|---|---|---|---|---|---|---|
| 2026-09-28 | Tolerance Bio, Inc. | MT-2990 | Not disclosed | Not disclosed | Not disclosed | Clinical stage; evaluated in clinical studies |